Drug Trial Radar · NCT06949137
Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture
Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
9
Actual
Start
Jun 20, 2025
Primary completion
Mar 6, 2026
Study completion Sep 6, 2026
Sponsor
- Lead sponsor
- HELP Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- First posted
- Apr 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 45 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of human umbilical cord-derived mesenchymal stem cells for injection (HMM910 ) in postmenopausal women with osteoporosis who are at high risk of fracture.
Conditions
- Osteoporosis in Post-menopausal Women
- Osteoporosis
Interventions
Human Umbilical Cord-derived Mesenchymal stem cellBiological
Intravenous infusion of human mesenchymal stem cells (HMM910 ) at 20-25 drops per minute
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Treatment-Related Adverse EventsTime frame: Within 4 weeks after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
HELP Therapeutics
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.